Nov 6 (Reuters) – India’s Gland Pharma reported a bigger-than-expected 58.3% jump in second-quarter profit on Friday, boosted by strong sales in its key European and US markets.
The Hyderabad-based company’s consolidated net profit of 2.91 billion rupees ($30.9 million) was up from 1.84 billion rupees a year ago, beating analysts’ average estimate of 2.75 billion rupees, according to data compiled by LSEG.
Here are some more details:
• Its US sales, which make up more than half of the total, rose 42% in the quarter ended September 30, while the European business climbed 30%
• Gland Pharma’s results have consistently improved since a recovery in production at its Cenexi units in France and Belgium in late 2025
• Disruption at these units had hurt the drugmaker’s results throughout most of last year
• Overall quarterly revenue rose 23.3% to 18.34 billion rupees, also beating estimates of 17.59 billion rupees
• Gland Pharma and several of its Indian generic drugmaker peers that derive a large share of their revenue from the US have been grappling with limited pricing power amid stiff competition in that market
• Larger rivals Cipla and Dr Reddy’s also reported subdued US sales during the second quarter
($1 = 94.1550 Indian rupees)
(Reporting by Kashish Tandon in Bengaluru; Editing by Shreya Biswas)
